Table 1.

Clinical characteristics and their correlations with CT erosion score. Data are mean (SD) unless indicated otherwise.

Clinical FeaturesPearson rP
Age, yrs56 (12)−0.050.66
Male sex, n (%)94 (94)0.24
Ethnicity, n (%)0.03
  Pacific42 (42)
  Māori18 (18)
  Non-Māori, non-Pacific40 (40)
Gout disease duration, yrs22 (11)0.200.051
No. subcutaneous tophi7.3 (7.1)0.62< 0.001
Serum urate, mmol/l0.38 (0.12)0.220.29
Serum creatinine, μmol/l97 (23)0.340.001
RANKL concentration, pmol/l0.28 (0.65)0.440.001
OPG concentration, pg/ml2214 (1272)0.270.006
Sclerostin concentration, pg/ml696 (338)−0.290.003
DKK-1 concentration, pg/ml3412 (1992)−0.080.46
FGF-23 concentration, pg/ml7.1 (11.8)0.180.08
P1NP concentration, μg/l56.9 (33.3)0.160.12
β-CTX concentration, ng/ml0.29 (0.16)0.070.46
  • Pearson r and p refer to correlation with CT erosion score.

  • P value shown for comparison of erosion scores between groups. CT: computed tomography; RANKL: receptor activator of nuclear factor-κB ligand; OPG: osteoprotegerin; DKK: Dickkopf 1; FGF-23: fibroblast growth factor 23; P1NP: procollagen type-1 N-terminal propeptide; CTX: collagen cross-linked C-telopeptide, type I.